期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 37, 期 9, 页码 779-788出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2016.06.002
关键词
-
资金
- Netherlands Organization for Scientific Research (VIDI) [917.11.349]
- Consejo Nacional de Ciencia y Tecnologia (CONACyT) [219707]
- Netherlands Organisation for Scientific Research (VICI) [918.56.601]
- Netherlands Organisation for Scientific Research (Spinoza)
- European Community (EC) [602633]
Migraine is a common episodic neurovascular brain disorder associated with increased risk of cardio- and cerebrovascular ischemia. Migraine headache is likely caused by activation of the trigeminovascular system and release of calcitonin gene-related peptide (CGRP). Monoclonal antibodies against CGRP or its receptor are currently being evaluated for the prevention of migraine attacks. Preliminary efficacy data are promising. However, because CGRP may act as a vasodilatory safeguard during cerebral and cardiac ischemia, CGRP blockade could transform transient mild ischemic events into full-blown infarcts. Here, we review the cerebro- and cardiovascular risks that might be associated with CGRP blockade and which clinical and preclinical studies should be conducted to better assess the potential safety issues of this new promising class of drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据